Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTD1 plus Capecitabine in Advanced Breast Cancer
NCT02253459Phase 3Completed
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Aug 2014
- Primary completion
- Sep 2016
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of utidelone in breast cancer, sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Started Aug 2014; status: completed.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02253459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253459.